Vaxcyte, Inc. (NASDAQ:PCVX) COO Sells $689,760.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 8,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $86.22, for a total value of $689,760.00. Following the completion of the transaction, the chief operating officer now owns 205,695 shares in the company, valued at $17,735,022.90. The trade was a 3.74 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jim Wassil also recently made the following trade(s):

• On Thursday, January 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $83.66, for a total value of $669,280.00.
• On Monday, December 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $92.49, for a total value of $739,920.00.

Vaxcyte Stock Up 2.0 %

NASDAQ PCVX traded up $1.70 on Tuesday, hitting $86.51. 1,752,866 shares of the stock were exchanged, compared to its average volume of 1,227,603. The company has a market cap of $10.78 billion, a PE ratio of -18.81 and a beta of 0.98. The company has a 50-day moving average price of $87.46 and a 200-day moving average price of $94.42. Vaxcyte, Inc. has a fifty-two week low of $58.10 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period in the previous year, the company earned ($0.91) EPS. As a group, equities research analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. The Goldman Sachs Group initiated coverage on Vaxcyte in a research note on Friday, December 20th. They set a “buy” rating and a $135.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $140.00 price objective on shares of Vaxcyte in a report on Wednesday, November 6th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte currently has a consensus rating of “Buy” and a consensus target price of $145.71.

Hedge Funds Weigh In On Vaxcyte

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its stake in shares of Vaxcyte by 2.4% during the fourth quarter. Bank of New York Mellon Corp now owns 421,938 shares of the company’s stock worth $34,540,000 after purchasing an additional 9,888 shares in the last quarter. Handelsbanken Fonder AB boosted its holdings in shares of Vaxcyte by 16.2% during the fourth quarter. Handelsbanken Fonder AB now owns 31,500 shares of the company’s stock valued at $2,579,000 after acquiring an additional 4,400 shares during the period. TimesSquare Capital Management LLC grew its position in Vaxcyte by 53.7% in the 4th quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company’s stock worth $33,860,000 after purchasing an additional 144,516 shares during the last quarter. CIBC Asset Management Inc boosted its position in shares of Vaxcyte by 5.5% during the fourth quarter. CIBC Asset Management Inc now owns 3,307 shares of the company’s stock worth $271,000 after buying an additional 171 shares during the period. Finally, Sanctuary Advisors LLC raised its stake in shares of Vaxcyte by 28.1% during the fourth quarter. Sanctuary Advisors LLC now owns 5,685 shares of the company’s stock valued at $465,000 after purchasing an additional 1,248 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.